Sarepta Therapeutics Inc. (NASDAQ:SRPT)
Bands
Volume
200 SMA
50 SMA
20 SMA
Videos
Alerts
Articles
Events
Old Forum Content for SRPT
Make a Forum Post Become a member to view recent forum posts. Already a member? Sign in here.
-
Lou: ...
My other high conviction holdings, now quite large positions that are well in the green are $ALNY $BA $ARDX $FTI $FROG (thanks @Scottrades), and $WELL. Lots of OTM short puts in $BA $FROG, some in $WELL, and a recent new stock position in $SRPT. Tw ... - Lou: @Lou $ET $EPD $MPLX $ALNY $BA $ARDX $FTI $FROG $WELL $SRPT $HUMA $DBRG $CAVA $WLDN Omitted my $VKTX (and short puts) and a relatively small position in $FIG.
- camaro69: $SRPT NICE VOLUME SPIKE it may have more
- woodman: $SRPT - https://www.bloomberg.com/news/articles/2025-08-18/fda-reinstates-sarepta-gene-therapy-after-parents-rally-for-duchenne-treatment?embedded-checkout=true With the Elevidys drama over for now (parent pressure causing the FDA to reverse its hold on the drug to permit resumed sales) - at least until the ticking-time-bomb next very serious adverse event - it seems that this is going higher. A move above $23 would get it back into the gap in earnest. That gap goes to about $35-$36.
- camaro69: @woodman $SRPT My thoughts also, just be prepared for the bomb again!
- woodman: @camaro69 $SRPT - Truth be told, every biotech is a ticking time bomb. It's just hard to hear the ticking for many of them.
- camaro69: @woodman $SRPT so right!!!! Just when you are ready for it to run higher it pants's me and then laughs! Says sucker!!!
- woodman: @camaro69 $SRPT - Biotech generally - with some wild successes have come plenty of nasty wounds.
- camaro69: $SRPT I believe it's over sold long
- camaro69: $SRPT working
-
woodman: Biotech - I'm long 3: $ARDX $VKTX $SRPT.
$ARDX - Ibsrela (tenapanor for IBS-C) selling very well and growing. It alone merits a higher share price. Xphozah (tenapanor for hyperphosphatemia) is gravy on top for now, but If Xphozah litigation is resolv ... - camaro69: @BarryC $SPY $QQQ Appreciate your candor. $SRPT has worked well this week. Trying to get through the 50 day. As of now, it will open higher. Hasn't been here in a while. I believe their earnings were good last week. been trading $SOFI and $TCNNF also
- camaro69: $SRPT trying to crawl out of it's mess. It's drug supposably didn't cause the child's death, the drug safe to use, probably more to the story.
- DavidK: @camaro69 $SRPT tried to research latest stays on halted / restricted drug in question. Bottom line do you know if it is now being allowed to be prescribed openly or restricted
- camaro69: $SRPT HOD might go
- camaro69: @DavidK $SRPT I don't know A lot of room above I believe they had good earnings, just makes you wonder about the safety of the drug in the back of your mind. Things change quick!
- woodman: $SRPT is interesting if the headwinds/drama over the hold and lifting of the hold on its Elevidys are now behind it. It's extremely cheap considering what it's expected to earn on its drug.
- Mikev200: $SRPT up 16% maybe they have news I don't see.
- woodman: $SRPT craziness afterhours. Trading halted on yet (more) news. https://www.fda.gov/news-events/press-announcements/fda-recommends-removal-voluntary-hold-elevidys-ambulatory-patients
- woodman: $SRPT - the "T" stands for turd.
- DavidK: @woodman $SRPT yep glad I sold down to only 300 shares yesterday . Still hurts . Not sure what to do . News doesn’t sound as promising as was lead to believe yesterday
- bigbartabs: @DavidK $SRPT ...I would go to 1 share, and set an alert for it to get back above its 8dema.
- woodman: @DavidK $SRPT - Biotech is a minefield to begin with and perhaps the easiest of the sectors to lose your dough. Looking at my scars, I'd say it's almost uninvestible and not worth the risk. $VKTX is my only longer than a short term chart trade right now. I have $SANA, too, but that is like any other chart-based trade. But SRPT specifically is a complete mess and I was stupid even to get involved, even if with only a small position. I didn't buy much because of the hot stove effect. Again, the scars....
- DavidK: $SRPT- News that dosage change and small quick trial might only be needed to get drug back on market as opposed to lengthy expensive trial.
- bwcarnation1: @DavidK $SRPT that would be great for patients and the company
- DavidK: @bwcarnation1 $SRPT yes I haven’t followed this story much but do recall hearing this was an overreaction and detrimental to some patients that really have to have this drug. Above my pay scale or knowledge but I bought 500 shares just now and looks like market likes the news
- woodman: @DavidK $SRPT - I was reading same as you posted. I bought a few. Not remortgaging the house. ;-)
- DavidK: @woodman $SRPT you would think a bounce maybe back up to 17 area on the chart might be feasible if no bad news or conflicting report comes out in the near term .
- woodman: @DavidK $SRPT - This FDA is unpredictable at best, and seems to have it out for SRPT. That's my concern. Everything will be driven by news and random speculation that will come out without notice.
- Henry: $SRPT Good Morning Barry roller coaster ride for this one. A third patient has died taking their drug.
- Henry: $SRPT The FDA asked the company to stop shipping their drug
- joelsg1: @Henry $SRPT But Juul vapes can stay on market.
- woodman: @joelsg1 $SRPT - The joys of biotech investing.
- joelsg1: @woodman $SRPT $CRSP!
- woodman: $SRPT - Sarepta Therapeutics, the gene-therapy company, changed its executive team and said it will lay off about one-third of its workforce. The restructuring is expected to save $400 million a year. Shares jumped 30% in premarket trading.
- Henry: @woodman $SRPT I posted last night there was news about a Black Box label so the can continue to market their drug
- woodman: @Henry $SRPT - I missed it. Thanks, Henry.
- joelsg1: @woodman $SRPT I was in $BMRN when it lost the rare disease competition to $SRPT by an eyelash. Neither drug was that effective but parents of kids with this terrible disease want/deserve some hope, so $SRPT got the nod. And the chart tells the tale.
- Henry: $SRPT Up 37% Gets permission to add Black Box for it's muscular therapy drug
- Wolf: $SRPT Not sure what kind of trade this would be. 10% short interest, so maybe some short covering. Shares fell 40% pre-bell Monday after the company said over the weekend that it is temporarily suspending shipments of Elevidys for non-ambulatory patients with Duchenne muscular dystrophy following a second reported case of death from acute liver failure.
- woodman: $SRPT - No position, but interesting story. It continues to struggle under the 50d on the daily chart. https://www.wsj.com/tech/biotech/a-3-million-gene-therapy-maker-at-a-bargain-price-1ce508bd
- woodman: $SRPT - interesting. https://www.biopharmadive.com/news/sarepta-elevidys-sales-duchenne-gene-therapy-second-quarter-2024/723677/
- woodman: $SRPT is at an interesting spot with this pullback to the 50d. It reports today amc. I think it could beat and raise guidance. But not sure I want to gamble on it.....
- woodman: $PFE $SRPT - Pfizer's DMD Phase 3 fail leaves SRPT (PDUFA 6/21) as the only game in town. https://www.fiercebiotech.com/biotech/pfizers-phase-3-gene-therapy-trial-fails-improve-function-boys-duchenne-muscular-dystrophy
- joelsg1: @woodman $PFE $SRPT Never liked $SRPT on MD since it got the nod over $BMRN, word then was it was close but FDA approved $SRPT to give some hope to families affected by MD, not that their drug worked that well. Tough nut to crack.
- woodman: @joelsg1 $PFE $SRPT $BMRN - I have no skin in the DMD TA. I think it will be approved, but it may have a strict/limiting label. The testimony of parents whose kids have improved quite a bit is compelling.
- Mikev200: $SRPT Sarepta Therapeutics (SRPT) reported earnings of $0.73 per share on revenue of $413.46 million for the first quarter ended March 2024. The consensus estimate was a loss of $0.07 per share on revenue of $372.80 million. The Earnings Whisper number was $0.03 per share. The company beat expectations by 2,333.33% while revenue grew 63.10% on a year-over-year basis. I guess not good enough :))
- camaro69: $SRPT up nice pre mkt on news
- camaro69: $SRPT holding it's gap up for the moment
- camaro69: $SRPT held its gap up for now
- GOOSE: $SRPT On P&F chart, AT A DOUBLE TOP, @84.0, 85.0 BREAKS IT GIVING A BUY SIGNAL, GOING TO BUY A WEE BIT JUST TO KEEP AN EYE ON IT.
- GOOSE: $SRPT BTO STOCK @ 83.98
- shoredriver: $SRPT.....glad I did not sell the 11/3 80's...
- GOOSE: TRADES: $UPST STO 11/10/23 28.50 CALLS @2.12, and 29.50 CALLS @1.75 $SRPT BTO STOCK @ 79.23 and 79.87 $SRPT STO 11/10/23 80.9 CALLS @1.85
- shoredriver: $SRPT....nice....started nibbling around 62....looking to swing as sell some of this Fridays calls....maybe 80's....
- shoredriver: $SRPT new HOD....yaaassss.....
- woodman: @shoredriver $SRPT - Nice job!
- GOOSE: I'm getting ready to sell $SRPT, earnings after bell. YOU????
- GOOSE: Out of $SRPT. TOMORROW IS ANOTHER DAY TO HAVE SOME FUN. ;>)
- Motorman: @GOOSE $SRPT Nice trade!
- wijimmy: $SRPT ..... OUCH !!!!!! DOWN -46% and reports TOMORROW !!!! down due to... Sarepta Therapeutics' Shares Plummet to 5-Year Low as Duchenne Muscular Dystrophy Results Miss Trial Goal.... ... ... Nice quick BOUNCE....... Morgan Stanley Adjusts Price Target on Sarepta Therapeutics to $146 From $183, Maintains Overweight Rating 10/31/2023 09:03AM • MT Newswires ... Nice quick BOUNCE.....
- scottrades: @wijimmy $SRPT Wow....
- GOOSE: A GAMBLE, not a trade: $SRPT BTO STOCK @61.25 One round lot.
- joelsg1: @wijimmy $SRPT When their DMD drug was approved initially by FDA over a competing drug from $BMRN, as I recall they overruled staff as it wasn't clear either drug really worked but there was great political pressure from parents of children with this terrible condition for some hopeful cure.. Coming home to roost now.
- GOOSE: A TRADE: $SRPT STO 11/10/23 65.0 CALL @3.75 Covered
- GOOSE: TRADE: $SRPT added 2 more round lots @63.67 & 64.85 Reporting tomorrow in the PM.
- GOOSE: A TRADE: $SRPT BTC 11/10/23 65.0 CALL @5.00 STO @3.75
- shoredriver: $SRPT....down 14% on FDA delay ..watching...
- Auto: $CVX $SRPT added long daily
- Nepenthe: @Auto $CVX $SRPT Do you know what's going on with $AQUA? Disappeared from my trading screen. Cheers.
- Auto: @Nepenthe $CVX $SRPT $AQUA $AQUA completes Acquisition with Evoqua the ticker XYL
- shoredriver: $SRPT....not bouncy....at least not yet...watching
- camaro69: $SRPT HOD
- Bridgemate: $SRPT ?
- Henry: @Bridgemate $SRPT FDA meeting today
- Bridgemate: @Henry $SRPT thank you
- scottrades: Some Earnings after the close today: $AMD $F $SBUX $ET $SMCI $LTHM $CZR $PAYC $LUMN $MTCH $SPG $CLX $CHK $OKE $YUMC $WU $PRTS $DVAX $TRVG $SAR $PRU $ARWR $BAND $NRDS $SRPT $CWH $OHI $PACB $DENN $BGFV $MUSA $EQX $HLF $INSP $SPT $ANDE $APLE $WELL $AFG $CRK $AKR $EXPI $CLW $HRZN $MTW $FRSH $LSI $EXR $ATGE $UNM
- shoredriver: $SRPT...ouch.....
- shoredriver: @shoredriver $SRPT ....NP.....
- woodman: @shoredriver $SRPT - Adam Feuerstein/STAT hit piece. Bouncing nicely afterward. Feuerstein has been attacking SRPT forever. He's a nutty often irrational guy who, by the way, has a political science degree. Nothing in the physical sciences or medicine. But somehow he's managed to get a reputation as a biotech know-it-all. Watching him over the years, he puts many companies on his sh*t list and they never come off. He never admits he's wrong about anything. And he has been wrong many times.
- woodman: $SRPT - good action, holding its move up through descending resistance a couple days ago. PDUFA 5/29; AdCom likely late this month or early next. I'm still in this with a position I started on collapse day 3/17. I'm thinking it goes higher into the AdCom, but the AdCom itself will move the stock one way or the other, for sure.
- sierramp: @woodman $ARDX $ETNB $PDSB $AMLX $ORMP $VKTX $DAWN $BMRN $CPRX $NWBO $SRPT $VRTX $XFOR #Biotech Thank you for this. Can't buy them using my usual process for evaluation but very, very interesting so attempting to come up with another way to evaluate. If you have time, would you share how they pass your test?
- woodman: @sierramp $ARDX $ETNB $PDSB $AMLX $ORMP $VKTX $DAWN $BMRN $CPRX $NWBO $SRPT $VRTX $XFOR #Biotech - Catalysts (trial data due; FDA decisions due, etc.), important therapeutic areas and potential moats, interesting combos with established companies and institutions, strong interest by people I respect. Not all of these necessarily apply to each and every one, but some of these elements apply to each. Not an exhaustive list, but what instantly came to mind. Fwiw, I provided a small bit of color on most of these in a prior recent post here that you can search for. The chart is a factor, but to a more limited extent - less so than my ordinary trading MO.
- pperlroth: @woodman $ARDX $ETNB $PDSB $AMLX $ORMP $VKTX $DAWN $BMRN $CPRX $NWBO $SRPT $VRTX $XFOR #Biotech These are great! Thank you for sharing as I often look to this industry as the payouts can be massive given potential takeovers AND potential FDA approvals for new drugs/therapies.
- woodman: Updated list of #Biotech that I'm currently in ($$ amounts vary; not in any particular order): $ARDX $ETNB $PDSB $AMLX $ORMP $VKTX $DAWN $BMRN $CPRX $NWBO $SRPT $VRTX $XFOR (bought today).
- scottrades: My notes: $SPY $QQQ Santa Rally? More like Santa Short Covering $GDX Going sideways $SLV Holding the 8EMA $XLE Choppy $XBI Tight $VRNA Consider more profits if you’re long $CPRX Don’t lose sight of this $VRTX Would like to see it tighten up $SRPT Working $CAH Holding the 8EMA $SHLS Still holding the 50 Day $ARRY Nice volume into the close $CROX Holding the 8EMA $G Tight weekly $Four High Handle $ELF Holding the 21 EMA $WPM Sold and bought some back $GOLD closed above the 8EMA
- woodman: Current #biotech and Big #Pharma that I'm in: $ARDX (gift drop 2 days ago; catalyst with news likely in January - see my prior posts) $CPRX (keeps going) $ORMP (strong today; catalyst into January for P3 results for oral insulin; also, CEO just talke ...
- camaro69: @scottrades $SPY $QQQ $DIA $UUP $SMH $XBI $TAN $XLV $XLE $OIH $BITO $AAPL $META $TSLA $MSFT $ENPH $ARRY $SHLS $FSLR $NVDA $ON $PENN $CPRX $ITCI $SRPT $PRVB $UNH $Great Video Scott. Thanks for going over the moving averages in depth.
- scottrades: My notes: $SPY At the 200 Day $QQQ At the 100 EMA $DIA Downside Reversal $UUP Under the 200 Day $SMH Above the 200 Day $XBI MAs are stacked $TAN Holding the 8EMA $XLV Working $XLE Traded tight all day, hard to find good setups $OIH Above the 50 Day, hard to find good setups $BITO Stopped at the 50 Day $AAPL Downside reversal $META Held the gap $TSLA at the 200 Week MA. $MSFT Rejected at the 200 Day $ENPH Still in an uptrend $ARRY Bought this today $SHLS Above all the MAs $FSLR At the 21 EMA $NVDA Above the 200 Day $ON At the 8EMA $PENN Out of the wedge $CPRX This is on the ATL $ITCI Clear resistance. $SRPT Watch 124 $PRVB from @lauralynnee in the forum. $UNH Watch 555
- lauralynnee: @scottrades $SPY $QQQ $DIA $UUP $SMH $XBI $TAN $XLV $XLE $OIH $BITO $AAPL $META $TSLA $MSFT $ENPH $ARRY $SHLS $FSLR $NVDA $ON $PENN $CPRX $ITCI $SRPT $PRVB $UNH Thanks @Scottrades for covering $PRVB tonight, and you got my name right!
- Angdionk: $SRPT bouncing off 21DMA
- scottrades: $SRPT Higher Lows and higher Highs. A bit extended above the 8EMA. Watch for a PB to the MAs.
- woodman: @scottrades $SRPT - This makes me sad. I had it and got shaken out, then let it get away. Congrats to those who didn't get faked out.
- woodman: $SRPT left me in the dust. I got out in early Nov., didn't pay attention afterward, and it has bounced back, now breaking out of its sideways range.
- jpoko13: $SRPT Big move into the blue
- woodman: $SRPT - Looking for something to kick that won't hurt my foot too much! This shook me out. It was a fake-out! I held for a while but sold when it collapsed under the 50d and then the last of it when it couldn't hold the channel. But it reversed back up, all the way to top of the channel, without me. It even broke through top of the channel this morning, though now falling back in.
- fiebs: $SRPT moving this morning
- woodman: $SRPT has moved back up to the 50d after a not so nice fall through it 2 weeks ago. If it rolls over here, it could be a decent short.
- woodman: $SRPT -Collapsing out of range, look out below. Stopped out of the shares I tried to pick off the bottom of the range. Glad I sold most before earnings.
- joelsg1: @woodman $SRPT Never liked this co. or their MD drug, ever since they beat $BMRN for govt. approval on dubious data. Almost any new drug would do better. Good riddance.
| Stock Price | $21.53 |
| Change | -1.01% |
| Volume | 2,006,070 |
Sarepta Therapeutics Inc discovers and develops RNA-based therapeutics for the treatment of rare and infectious diseases. Its lead product candidate is eteplirsen.
Request Video of SRPTAlready a member? Sign in here.
Past Month
Leading Peers
-
$26.02 153.79%
-
$33.05 142.61%
-
$16.56 89.15%
Past Month
Lagging Peers
-
$15.30 -58.16%
-
$27.27 -44.32%
-
$19.51 -43.69%
Dan Fitzpatrick
Stock Market Mentor gives you EVERYTHING you need to succeed in the market; all in one place. How easy is that? Dan Fitzpatrick and his elite community of traders share trading ideas, strategies and much more. Dan Fitzpatrick--a world class Technical Analyst, trading coach and regular CNBC contributor--gives you access to all of this with a 30 day trial membership for just $7.77. Get started TODAY and start trading better TOMORROW with the following premium content:
- Nightly video Strategy Sessions with a game plan for tomorrow
- Got a stock you want Dan to look at? Just ask.
- Patent pending video alerts instantly delivered to you when one of Dan’s trading signals is triggered. This is not your typical price alert. This is a short video explaining the action you need to take to make money. No more “Woulda, coulda, shoulda”
- Access to over 90,400 stock analysis videos
- Access an ever expanding library (90,400) of educational videos that will save you time and make you money
Join a team of friends and traders that have one thing in common; a burning desire to succeed.
Become a Member Today!
Gain immediate access to all our exclusive articles, features, how-to's, discussion group and much more...
Satisfaction Guaranteed!
Your Stock Market Mentor membership comes with a 30 day, no questions asked, 100% money back guarantee!